TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

TELA Bio, Inc.NASDAQ: TELA

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 72.3%

Gross margin was 72.3% in Q2 FY2026, up 2.4 pp from a year earlier. On a trailing-twelve-month basis it was 67.8%, up 0.5 pp year over year. Over 3 fiscal years it widened by 2.4 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
72.3%+6.6 pp QoQ
Last fiscal yearDec 2025
67.7%+0.6 pp YoY
LTMJun 2026
67.8%+0.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.4 pp——
1 year+0.6 pp——
3 years+2.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
67.7%
Year-over-year change
+0.6pp

Gross Margin vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 gross margin of 67.8% is the 3rd highest of the 7 companies compared; the peer median is 41.2%.
  • Its year-over-year change of +0.5 pp is the 2nd highest of 6, against a peer median of -0.3 pp.
  • Over three fiscal years its change of +2.4 pp compares with a peer median of +0.0 pp.
TELA Competitors Peer median
Gross Margin for TELA and competitors
Company Period LTM level YoY 3-year change
CUECue Biopharma, Inc.LTM Mar 202699.8% -0.2 pp+0.0 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 202687.2% +59.0 pp—
TELATELA Bio, Inc.LTM Jun 202667.8% +0.5 pp+2.4 pp
MDAISpectral AI, Inc.LTM Mar 202644.7% -0.3 pp+2.7 pp
SRTSSensus Healthcare, Inc.LTM Mar 202637.7% -18.3 pp-23.4 pp
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
EQEquillium, Inc.FY2025— ——
Peer median (excluding TELA) 41.2%-0.3 pp+0.0 pp

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.46M41.42M58.45M69.3M80.28M
Cost of Revenue10.65M14.37M18.34M22.81M25.93M
Gross Profit18.81M27.04M40.11M46.49M54.34M
Gross Margin63.9%65.3%68.6%67.1%67.7%
Research & Development6.74M8.94M9.62M8.81M9.22M
Selling, General & Admin41.52M57.11M74.57M79.37M78.88M
Operating Expenses48.26M66.05M84.19M80.6M88.1M
Depreciation & Amortization535K1.19M808K1.01M1.01M
EBITDA(29.14M)(39.06M)(40.63M)(31.68M)(32.35M)
EBITDA Margin-98.9%-94.3%-69.5%-45.7%-40.3%
Operating Income(29.45M)(39.01M)(44.08M)(34.12M)(33.76M)
Operating Margin-100.0%-94.2%-75.4%-49.2%-42.0%
Interest Income00000
Interest Expense3.6M4.05M5.22M5.29M5.25M
Other Income / Expenses(3.83M)(5.29M)(2.59M)(3.87M)(4.85M)
Income Before Tax(33.28M)(44.3M)(46.66M)(37.99M)(38.6M)
Pre-Tax Margin-112.9%-106.9%-79.8%-54.8%-48.1%
Income Tax Expense000(144K)230K
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Net Margin-112.9%-106.9%-79.8%-54.6%-48.4%
EPS (Basic)(2.30)(2.73)(2.04)(1.33)(0.83)
EPS (Diluted)(2.30)(2.73)(2.04)(1.33)(0.83)
Weighted Avg Shares14.47M16.27M22.87M28.53M46.95M
Weighted Avg Shares (Diluted)14.47M16.27M22.87M28.53M46.95M

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.